Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

Moses Badio  
PREVAIL

Edouard Lhomme  
Universite de Bordeaux  
https://orcid.org/0000-0003-0214-1694

Mark Kieh  
PREVAIL

Abdoul Habib Beavogui  
Centre National de Formation et de Recherche en Santé Rurale de Mafèriniah

Stephen B Kennedy  
PREVAIL

Seydou Doumbia  
Universite des Sciences des Techniques et des Technologies de Bamako

Bailah Leigh  
University of Sierra Leone College of Medicine and Allied Health Sciences

Samba O Sow  
Centre pour le Développement des vaccins

Alpha Diallo  
INSERM

Daniela Fusco  
INSERM

Matthew Kirchoff  
National Institute of Allergy and Infectious Diseases

Monique Termote  
Universite de Bordeaux

Renaud Vatrinet  
INSERM

Deborah Wentworth  
University of Minnesota
Study protocol

Keywords: Ebola, Vaccine, Clinical Trials, Protocol

DOI: https://doi.org/10.21203/rs.3.rs-30774/v1

License: ☇️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction

The Ebola virus disease (EVD) outbreak in 2014–2016 in West Africa was the largest on record and provided an opportunity for large clinical trials and accelerated efforts to develop an effective and safe preventative vaccine. Multiple questions regarding the safety, immunogenicity, and efficacy of EVD vaccines remain unanswered. To address these gaps in the evidence base, the Partnership for Research on Ebola Vaccines (PREVAC) trial was designed. This paper describes the design, methods, and baseline results of the PREVAC trial and discusses challenges that led to different protocol amendments.

Methods

This is a randomized, double-blind, placebo-controlled phase 2 clinical trial of three vaccine strategies against the Ebola virus in healthy volunteers 1 year of age and above. The three vaccine strategies being studied are the rVSVΔG-ZEBOV-GP vaccine, with and without a booster dose at 56 days, and the Ad26.ZEBOV,MVA-FN-Filo vaccine regimen with Ad26.ZEBOV given as the first dose and the MVA-FN-Filo vaccination given 56 days later. There have been 4 versions of the protocol with those enrolled in Version 4.0 comprising the primary analysis cohort. The primary endpoint is based on the antibody titer against the Ebola virus surface glycoprotein measured 12 months following the final injection.

Results

From April 2017 to December 2018, a total of 5,002 volunteers were screened and 4,789 enrolled. Participants were enrolled at 6 sites in four countries (Guinea, Liberia, Sierra Leone, and Mali). Of the 4,789 participants, 2,560 (53%) were adults and 2,229 (47%) were children. Those < 18 years of age included 549 (12%) aged 1 to 4 years; 750 (16%) 5 to 11 years; and 930 (19%) aged 12–17 years. At baseline, the median (25th, 75th percentile) antibody titer to Ebola virus glycoprotein for 1,090 participants was 72 (50, 116) EU/mL.

Discussion

The PREVAC trial is evaluating - placebo-controlled - two promising Ebola candidate vaccines in advanced stages of development. The results will address unanswered questions related to short- and long-term safety and immunogenicity for three vaccine strategies in adults and children.

Trial registration

Clinicaltrials.gov, NCT02876328. Registred 23 August 2016, https://clinicaltrials.gov/ct2/show/NCT02876328

Introduction
The Ebola virus disease (EVD) outbreak in 2014–2016 in West Africa was the largest since the discovery of the virus in 1976 with more than 28,000 confirmed cases of EVD and 11,000 deaths in Guinea, Liberia and Sierra Leone (ref: WHO Ebola situation report 2016). The West-African outbreak prompted the rapid clinical evaluation of vaccine and therapeutic candidates that were in early development. As evidenced by the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC) ongoing since August 2018, along with other public health measures, efforts to develop an effective and safe vaccine against Ebola virus disease must continue [1].

By the end of 2015, new cases of EVD in West Africa had dramatically decreased. An open-label, cluster-randomized, ring vaccination trial conducted in Guinea, the “Ebola ca sutit” trial, randomized contacts and contacts of contacts to receive the Merck/New Link rVSVΔG-ZEBOV-GP vaccine immediately after randomization or 21 days later. There were no cases of Ebola virus disease 10 days or more following vaccination among 2108 contacts and contacts of contacts who were vaccinated immediately compared to 10 such cases in 1429 contacts and contacts of contacts who initially consented to receive vaccination 21 days after randomization [2]. In that trial, which was conducted mainly in adults, no EVD events occurred more than 10 days after vaccination. Based upon these and other data this vaccine has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the prevention of Ebola virus disease in individuals 18 years of age and older. No immunogenicity and limited safety data were collected in the “Ebola ca sutit” trial, especially in children. Two other vaccine strategies, the single-dose GlaxoSmithKline (GSK) ChAd3-EBO Z (replication-deficient Chimpanzee adenovirus type 3-derived vector encoding the Ebola virus Zaire [EBO Z] GP) vaccine and the Johnson & Johnson (J&J) 2-dose heterologous vaccination regimen, Ad26.ZEBOV, MVA-FN-Filo, have completed phase 2 testing. The heterologous two-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen has shown an acceptable safety profile, was well-tolerated and immunogenic in healthy 18–50 year-old adults volunteers from France and England [3] and Africa countries [4,5]. Data on safety, tolerability and immunogenicity from multiple studies supported the submission of European marketing authorization applications for this investigational Ebola two-dose heterologous vaccine regimen, which have been granted accelerated assessment by European Medical Agency. In addition, safety and immunogenicity up to 12 months after vaccination of the rVSVΔG-ZEBOV-GP and ChAd3-EBO Z vaccine have been evaluated in a phase 2, placebo-controlled trial of adults in Liberia (Partnership for Research on Ebola Virus in Liberia I [PREVAIL I]) [6]. The planned phase 3 component of PREVAIL I could not be completed because of the decline in cases of EVD resulting from public health efforts.

While there was substantial progress in the development of Ebola vaccines during the 2014–2016 West African epidemic, multiple questions regarding the safety and efficacy of EVD vaccines remain unanswered, including the durability and the immediacy of immune responses generated by different vaccine strategies with and without a booster, and the safety of these Ebola vaccines in special populations, particularly children.

To address these gaps, a phase 2 trial, the Partnership for Research on Ebola Vaccines (PREVAC) trial, was designed and initiated in 2017 to compare three vaccine strategies with placebo in adults and
children in Guinea, Liberia, Mali and Sierra Leone.

**Methods**

**Trial design**

The PREVAC trial is a randomized, double-blind, superiority, placebo-controlled phase II clinical trial evaluating three vaccine strategies against the Ebola virus.

We have conducted this trial as per the recommendations for interventional trials (SPIRIT). The final reporting of this trial will be in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement.

**Trial location**

Healthy volunteers were enrolled at 6 sites in four countries: Guinea at two sites (Landreah located in an urban area in Conakry and Maferinyah, a rural area in the Forecariah region), Liberia (Redemption Hospital in Monrovia), Mali at two sites (Center for Vaccine Development (CVD) and the University Clinical Research Center (UCRC), both in the capital Bamako) and Sierra Leone (Mambolo, a rural community in Kambia District, northern Sierra Leone).

**Eligibility criteria**

Inclusion into the study was based on the following criteria: 1) Willingness to participate and sign informed consent/assent, 2) Age ≥ 1 year, 3) Planned residency in the area of the study site for the next 12 months, and 4) Willingness to comply with the protocol requirements.

Participants were excluded from enrolment based on the following: 1) Fever > 38°C, 2) History of EVD (self-report), 3) Pregnancy (a negative urine pregnancy test was required for females of child-bearing potential), 4) Positive HIV test for participants < 18 years of age, 5) Reported current breast-feeding, 6) Prior vaccination against Ebola, 7) Any vaccination in the past 28 days or planned within the 28 days after randomization, 8) In the judgment of the clinician, any clinically significant acute/chronic condition that would limit the ability of the participant to meet the requirements of the study protocol.

**Objectives**

The primary aim of the study is to evaluate the durability and immediacy of the antibody response to vaccination. The primary objective of the trial is to compare each of the three vaccine strategies with the pooled placebo group (3 pair-wise comparisons) for antibody responses 12 months after randomization (durability of response). This will be addressed separately for adults and children. Other objectives stated in the protocol are included in Appendix 1.

For the pharmaceutical companies providing the vaccines, information is also being collected to support regulatory filings.
Interventions

The three vaccine strategies being studied are the rVSVΔG-ZEBOV-GP vaccine, with and without a booster dose at 56 days, and the 2-dose heterologous vaccination regimen Ad26/MVA. One (1) mL from a 3 mL syringe of the rVSVΔG-ZEBOV-GP vaccine was administered for the prime and booster vaccination. The Ad26/MVA requires a 0.5 mL administration of Ad26.ZEBOV from a 3 mL syringe for the first vaccination dose and second dose vaccination of MVA-BN-Filo (0.5 mL from a 3 mL syringe) at 56 days.

The 2-dose heterologous vaccination regimen Ad26.ZEBOV,MVA-BN-Filo (0.5 mL from a 3 mL syringe for both doses) is comprised of an Ad26.ZEBOV vaccine which consists of a single recombinant, replication-competent human Ad26 vector, constructed to express the Ebola virus Mayinga GP. The second dose with MVA-BN-Filo at 56 days encodes the GP of Sudan virus (SUDV; formerly known as Ebola Virus Sudan), EBOV (formerly known as Ebola Virus Zaire), and Marburg Virus (MARV) Musoke, and the nucleoprotein of Tai Forest virus (TAFV; formerly known as Côte d'Ivoire ebolavirus). The Ad26.ZEBOV,MVA-BN-Filo vaccination regimen was given at the same dose in Versions 2.0, 3.0, and 4.0 of the PREVAC protocol. Version 1.0 was never implemented.

The rVSVΔG-ZEBOV-GP vaccine is comprised of a single rVSV isolate (11481 nt) modified to replace the gene encoding the VSV G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain) (1 mL IM administration). The rVSVΔG-ZEBOV-GP vaccine was not used in Version 2.0. The rVSVΔG-ZEBOV-GP dose was given as a 2-fold diluted dose (approximately $5 \times 10^7$ plaque-forming units [pfu/mL]) in Version 3.0 and was given as an undiluted dose (geometric mean of available assays $9.4 \times 10^7$ pfu/mL) in Version 4.0. The doses of rVSVΔG-ZEBOV-GP used in Versions 3.0 and 4.0 are referred to as the diluted and undiluted doses, respectively.

The placebo is sterile normal saline (sodium chloride 0.9 percent for injection, United States Pharmacopeia, preservative-free).

Study setting

Initially it was envisaged that eligible participants would be randomized to one of the following five groups in a 2:1:2:1:1 allocation: 1) Ad26.ZEBOV (prime vaccination at day 0) (0.5 mL) followed by a second dose with MVA-BN-Filo (0.5 mL) at 56 days; 2) placebo (at randomization and at 56 days) (0.5 mL); 3) rVSVΔG-ZEBOV-GP (prime at day 0) (1 mL) followed by placebo boost (1 mL) at 56 days; 4) rVSVΔG-ZEBOV-GP (prime at day 0) (1 mL) followed by rVSVΔGZEOBV-GP booster dose (1 mL) at 56 days; and 5) normal saline placebo (prime at day 0 and boost at 56 days) (1 mL) (Fig. 2). The study design included two placebo groups because the Ad26.ZEBOV and rVSVΔG-ZEBOV-GP vaccines were administered at different volumes and therefore each required a different placebo to match their specific volume of injection. For the primary analyses, the two placebo groups will be pooled.

A week prior to the commencement of enrollment for version 1.0 of the PREVAC trial protocol, an ongoing open-label study (the PREPARE study; ClinicalTrials.gov Identifier: NCT02788227) evaluating the safety...
and immunogenicity of the rVSVΔG-ZEBOV-GP vaccine among healthcare workers in the United States and Canada was temporary paused because 3 out of the 9 initial participants who had received the rVSVΔG-ZEBOV-GP vaccine reported arthritis. A vaccine lot investigation was undertaken which resulted in no quality findings. Due to site readiness in both Guinea and Liberia, while the lot investigation was ongoing, the protocol was revised to version 2.0 to exclude the rVSVΔG-ZEBOV-GP and matching placebo arm. Thus, the PREVAC trial commenced with a two-arm strategy and randomized participants ≥ 12 years of age to the Ad26.ZEBOV first dose (0.5 mL) followed by an MVA-BN-Filo second dose (0.5 mL) at 56 days or to matching placebo in a 2:1 randomization ratio (Fig. 2 – top panel). Version 2.0 aimed to enroll up to 600 participants to allow migration quickly to the original five arm randomization.

Even though no quality finding were found in the initial lot of rVSVΔG-ZEBOV-GP vaccine, a new lot was prepared. Upon review of the certificate of analysis of this new lot (release potency of $9.4 \times 10^7$ pfu/mL), it was decided to initially give the rVSVΔG-ZEBOV-GP vaccine at a 2-fold dilution (approximately $5 \times 10^7$ pfu/mL) which the study team referred to as the diluted dose. In June 2017, the protocol was amended and version 3.0 included randomization to 5 groups with the rVSVΔG-ZEBOV-GP vaccine groups being given the diluted dose (Fig. 2 – middle panel). As a safety precaution, enrollment was staggered by age group, starting with children aged 12–17 and adults. After 70 children aged 12–17 had been enrolled, safety data until Day 28 were reviewed by an independent Data and Safety Monitoring Board (DSMB), which identified no safety concerns and recommended opening enrollment to children aged 5–11 years. The procedure was repeated for the 5–11 and 1–4 age groups. In each age group, a DSMB review was conducted after 70 children were enrolled and followed for 28 days, before enrollment was opened to the next younger age group. It was decided that once the safety of the diluted dose of rVSVΔG-ZEBOV-GP had been established in children, the trial protocol would be amended to use the undiluted rVSVΔG-ZEBOV-GP vaccine.

In April 2018, after the safety of all three vaccine strategies, including the diluted dose of rVSVΔG-ZEBOV-GP, had been determined in each of three age groups of children (1–4, 5–11, and 12–17 years) by the independent DSMB, the PREVAC protocol was again amended. This version of PREVAC (version 4.0) follows the design originally planned (version 1.0) and that of version 3.0 except that the undiluted dose of the rVSVΔG-ZEBOV-GP vaccine ($9.4 \times 10^7$ pfu/mL) was to be used (Fig. 2 – bottom panel). The enrollment targets in version 4.0 were 1,400 children aged 1–17 years and 1,400 adults. The investigators of PREVAC agreed that the primary results would be based on data from version 4.0.

Both versions 2.0 and 3.0 of the study protocols were implemented in Guinea at Landreah and Maferinyah sites and at Redemption Hospital in Liberia. Protocol version 4.0 was implemented in these three sites and also in the CVC and UCRC sites in Mali and at the Mambolo site in Sierra Leone.

**Randomization and blinding**

The randomization groups and allocation ratio for each version of the protocol are presented in Fig. 2. For each vaccination center, the randomization schedule was prepared centrally, using block randomization to ensure the desired allocation ratio for each vaccination center.
Syringes were prepared one by one (whenever a participant was ready to be randomized) at the local study pharmacies by unblinded staff not involved in any other trial procedure. The syringe content (type of vaccine or placebo) was defined according to a central list that had been prepared by the University of Minnesota prior to the start of the trial, reflecting the above mentioned specifications for the randomization schedule. Allocation concealment was achieved by the use of a computer application that only revealed the next entry on the list one by one to the on-site pharmacy staff. The prepared syringe was labeled with a unique Syringe identifier (SID) and a bar code identifier tear-off label. To ensure blinding of the remaining site staff and the trial participants, syringe content was masked by a label covering the whole syringe. Although it cannot be excluded that the staff administering the vaccine could distinguish between the syringes containing 0.5 mL or 1 mL, they did not know whether the syringe contained active vaccine or placebo. At the time of vaccination, the tear-off label on the syringe with the SID was attached to the baseline Case Report Form (CRF) creating the primary link between the vaccine administered and the Participant identification (PID). This event is considered the point of randomization, and ensures that all randomized participants receive an injection, active or placebo. The syringes for the booster vaccination at day 56 were prepared at the local pharmacies, filled with an active vaccine or placebo depending on the participant's random assignment, and labeled with the PID. The laboratories carrying out the safety and immunogenicity analyses were blinded to the random assignment. Study participants and clinical staff assessing the study participants for safety and laboratory outcomes will remain fully blinded until all participants from the three protocol versions have completed 12 months of follow-up and results become available. Procedures were put into place to break the blind if necessitated by a medical emergency. If unblinding of a participant for safety reasons was required, it was documented.

**Study Endpoints**

The primary endpoint is the GP-EBOV antibody response 12 months after randomization. This is the primary endpoint that will be used to compare the immunogenicity of the three vaccine strategies with placebo. Other endpoints are as follows:

- For rVSVΔGZEOV-GP arms only, GP-EBOV antibody response at Day 28 after vaccination will be used for regulatory purposes for comparison to other studies and for bridging children to adults.
- For the Ad26.ZEBOV,MVA-BN-Filo vaccine arm only, GP-EBOV antibody response at Month 3 after randomization (approximately 28 days after the second dose of vaccine) will be used for regulatory purposes.

The primary analysis will be performed separately, for adults and children, and will exclude participants with elevated antibody titers at baseline.

Antibodies to the Ebola virus GP will be measured with the Filovirus Animal Nonclinical Group (FANG) ELISA assay [7]. The precise definition of antibody responders will be defined prior to unblinding of the study results. Other assays may also be used. If a correlate of protection is identified, stored sera will be
used to measure the correlate and carry out comparisons of the three vaccine strategies with placebo and with one another.

**Data collection plan**

Time and events schedule for baseline and regularly scheduled follow-up visits in the PREVAC study is described in Fig. 1. After it had been established that volunteers met the eligibility criteria and informed consent had been obtained from them or, in the case of children, a parent or guardian background data were collected. Demographics and a short medical history were obtained, blood was drawn as specified by the protocol, and then participants then received their first dose of the vaccine (“prime vaccination”). Randomization occurred at the point of vaccination as described above. For 30 minutes after the vaccination, participants were watched closely, injection site reactions and targeted symptoms were assessed, and possible grade 3 or 4 adverse events were recorded.

After the prime vaccination at study entry, initial follow up visits occurred at: 7 (± 3 days), 14 (± 3 days), and 28 (± 7 days) days. The booster dose of vaccine was administered on day 56 (53 to 66 days) with further follow-up visits at 63 days (7 ± 3 days after the booster vaccination), at 3 months (± 14 days), 6 months (± 1 month), and 12 months (± 1 month). Visits will continue at 24 (± 6 month), 36 (± 6 month), 48 (± 6 month) and 60 (± 6 month; ± 1 month) months as part of the PREVAC-UP study. At each follow-up visit up to Month 3, injection site reactions, targeted symptoms, and grade 3 or 4 adverse events that occurred since the previous visit are reported. At all follow-up visits, malaria and serious adverse events (SAEs) are reported, the temperature is recorded, and blood is drawn and stored for future immunogenicity assessments and other research.

For children, additional data were collected. Blood chemistries were assessed prior to the prime and booster vaccination at baseline and day 56 respectively, and 7 days after each vaccination. Also, during the first week following the prime and booster vaccination, daily contacts were made with children to assess injection site reactions, targeted symptoms and serious adverse events (SAEs), and body temperature.

Blood samples are collected at each site and processed according to their final use. A local laboratory analyzed blood samples at day 0 for adults and at day 0, 7, and 63 for children and adolescents for blood chemistry and hematology to assess potential vaccine toxicities. Laboratory values are graded for severity according to the Division of AIDS (DAIDS) Adverse Event Grading tables. Serology for HIV and syphilis was performed prior to randomization using rapid tests. If the participant had a positive HIV or syphilis test, he/she was be offered post-counseling and was referred to a pre-identified health structure for treatment. All countries use their own normal ranges as a reference. For Guinea, the Ghana values from Dooso et al [8,9] were used, for Liberia those used in PREVAIL 1 [6] were adopted, for Sierra Leone they were those used for the EBL3001 trial (NCT02509494), and for Mali the normal values used were those from Khone et al [10].
The FANG assay to measure the antibody response to Ebola glycoprotein is performed at the Liberian Institute for Biomedical Research (LIBR) laboratory in Monrovia for participants from Guinea and Sierra Leone, at the UCRC for participants from Mali, and at the NIAID Integrated Research Facility (IRF) (Maryland, USA) for participants from Liberia. Aliquots are shipped from sites to the relevant laboratory at regular intervals. Quality controls for intra- and inter-laboratory reproducibility are performed on a regular basis. Additional antibody response testing using a validated FANG assay will be performed for specific time-points (day 0, day 28, month 3 and month 12) at Quest diagnostics Clinical Laboratories Inc., San Juan Capistrano, US (FOCUS) as part of the regulatory activities of Merck and JnJ.

A CRF with a unique PID is completed for each participant consented and screened. The CRF is an eCRF developed with Ennov Clinical in English and French. Due to logistical hurdles, direct electronic data collection was not an option. Therefore, the clinical data are collected on paper CRF Forms and then entered in the eCRF the same day. Laboratory results conducted by the study team are directly extracted for the local Laboratory information management system and transferred on a daily basis to the centralized data center (EUCLID/FCRIN Clinical Trials Platform, Inserm/Univ Bordeaux, France).

Source Data Verification was done by regular on-site monitoring under the responsibility of the sponsors on site to ensure data integrity, and moreover remote monitoring was done in almost real time to identify trends and potential problems that go beyond just transcription problems from source documents.

**Sample size and statistical analysis**

The sample size for version 4.0 of the protocol was calculated to provide power to compare safety and immunogenicity separately for adults (N = 1,400) and children (N = 1,400). The sample size is greater than that which is required to address the primary objectives because, if a correlate of protection is identified, the vaccine strategies will be compared with one another for that correlate using an intention to treat analysis. Expected differences between vaccine groups may be smaller than comparisons with placebo and the correlate may have greater variability than the assay which will be used to measure antibody titers to address the primary, secondary and exploratory objectives. The larger sample size will also permit the exploration of subgroups and preserve power in the event there are more participants with elevated antibodies at baseline than anticipated.

With a type 1 error = 0.0167 (2-sided) to adjust for the three comparisons, separately for adults and for children in all age groups combined, and power = 0.90, even if the percent with a positive antibody response at 12 months is 50% in a vaccine group, with equal allocation, approximately 30 participants per group (60 participants in total) are needed assuming the percent in the placebo group with a positive antibody response is approximately 7%. With unequal allocation as for the rVSVΔG-ZEBOV-GP with the booster versus placebo comparison, a total of 63 participants (21 vaccinated with rVSVΔG-ZEBOV-GP with a boost and 42 vaccinated with placebo), a difference of 50% versus 7% can also be detected at 12 months with 87% power. These sample size estimates indicate that power for the planned subgroup analysis by age is also appropriate.
The planned sample size is also adequate for the comparisons with placebo if more than 4% of participants are antibody positive at baseline and excluded from the primary analysis, and if there are some missing data at 12 months of follow-up.

More information about the statistical analysis of the PREVAC trial is described in Appendix 2.

Substudies

There are currently two substudies ongoing and two planned in PREVAC. The immunological substudy is being conducted in Guinea with the primary objective of evaluating the T cell responses induced by the two vaccines candidates (rVSVΔG-ZEBOV-GP and Ad26.ZEBOV/MVA-BN-Filo) in adults and their persistence until one year after vaccination and longer (middle/long term). The second substudy, being conducted in Liberia, is investigating viral shedding of the rVSVΔG-ZEBOV-GP vaccine. The objective of this sub-study is to estimate the proportion of children who shed vaccine virus and to quantify the rVSVΔG-ZEBOV-GP vaccine shedding in children (participants aged < 18 years) after the prime and boost vaccinations. A third sub-study, assessing the impact of malaria infections on immune responses to the vaccines, is planned to take place in Sierra Leone and Guinea. A fourth sub-study, aiming to identify multi-level determinants of participant retention in the PREVAC trial to develop recommendations that will benefit future clinical research in resource limited settings affected by Ebola and other infectious diseases, is planned to take place in the four countries.

Trial governance

The Partnership for Research on Ebola Vaccinations (PREVAC) was established as an international consortium at the end of the West-African outbreak in 2015 to focus on Ebola research activities and to prevent or respond effectively to the next potential Ebola outbreak. The consortium includes research and academic institutions (the French Institute for Health and Medical Research [Inserm], the London School of Hygiene & Tropical Medicine [LSHTM], the US National Institutes of Health [NIH], the Universities of Bordeaux and Minnesota), health authorities and scientists from four Ebola-affected countries (Guinea, Liberia, Sierra Leone, and Mali), non-governmental organizations (the Alliance for International Medical Action and Leidos Biomedical Research, Inc) and pharmaceutical companies (MSD, Janssen Vaccines & Prevention B.V., and Bavarian Nordic). Members of the PREVAC study group conducting the vaccine trial are listed in Appendix 3.

Trial governance is detailed in Appendix 4 - Fig. 1. The trial is being conducted under the direction of a Trial Steering Committee (TSC), which provides overall supervision for the trial on behalf of the three sponsors (Inserm, LSHTM, NIH) and the host countries. Members of the TSC (Appendix 4) are blinded to interim safety and immunogenicity results.

An Executive Committee is composed of representatives of the sponsors and the coordinating investigator. Ad hoc meetings of the executive committee are organized when a sponsor-level discussion is needed. The executive committee also has the final say in the event consensus is not reached between TSC members.
A DSMB provides independent, expert oversight for the trial and monitors accumulating safety data for adults and children in each age group (1–4, 5–11, and 12–17 years) using reports provided by unblinded statisticians from the University of Minnesota (Division of Biostatistics, Minneapolis, USA).

The day-to-day operations and management of the trial are coordinated by the Trial Management Team (TMT). Daily monitoring of inclusions and retention rates are carried out in the central database, and blind reports are made available to the TMT via a secure website by a blinded statistician from EUCLID/FCRIN Clinical Trials Platform (Inserm/Univ Bordeaux, France). In coordination with the sites, this close monitoring has helped to achieve approximately the same number of children in each age group and a gender balance in both children and adults.

A centralized pharmacovigilance service has been implemented for trial safety management. Adverse events (AEs) occurring in enrolled participants are reported by investigators as soon as they become aware of them. All serious adverse events (SAEs) are reported to the sponsors immediately and no later than 24 hours after the investigator becomes aware of them. The medical officer (MO) responsible for pharmacovigilance firsts performs a partial unblinding of a potential suspected unexpected serious adverse reaction (SUSAR) to assess whether the SAR is unexpected for either product. If the event is unexpected for the product arm assigned (vaccine or matched placebo), the MO asks to be fully unblinded to determine whether the participant received active vaccine or placebo. This full unblinding is also performed via the web-based unblinding application monitored by the University of Minnesota. All SUSARs or other new safety data that would constitute new information for competent authorities are reported to the DSMB. The DSMB could recommend to the sponsors that vaccination be placed on hold or discontinued.

**Ethical and regulatory aspects**

During the enrollment process, there was widespread communication with local communities about the trial. Potential participants joined a detailed group information session prior to an individual session that included the signing of an informed consent form if they agreed to enroll. A flip chart describing the study was used to ensure that illiterate volunteers and minors understood the study requirements and risks and benefits in the presence of an impartial witness. In Liberia and Sierra Leone, minors aged 7–17 years signed an informed assent form after their parents/guardian provided consent for their participation in the study. Assent was not required in either Guinea or Mali. Minors who declined participation in the study after reviewing the assent materials were not enrolled even if their parent(s) or legal guardian consented to their participation.

The study protocol, the informed consent and assent forms (Appendix 5), including participants’ information materials, were approved by ethics committees of the sponsors (INSERM IRB 00003888, LSHTM) and the implementing countries (Guinea, Liberia, Mali, and Sierra Leone) before each version of the protocol was implemented. NIH established an institutional reliance agreement with INSERM to rely upon the INSERM ethics committee. The study is registered at [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) (NCT02876328) and in the Pan African Clinical Trials Registry (PACTR201712002760250).
The data of this trial will be disseminated through national and international conferences and peer-reviewed publications.

**Social mobilization**

Community-level social mobilization activities were developed in each site to engage local populations in interventional research and thus facilitate study enrollment. Site-level procedures were also developed to support participant retention, including visit incentives, participant tracking, digital and community-based outreach, and use of community champions and community mobilization techniques.

**Results**

**Enrollment rate and retention**

From April 2017 to December 2018, six sites in the four collaborating countries (Guinea, Liberia, Mali and Sierra Leone) screened 5,002 subjects and enrolled 4,789 participants in one or other version of the study protocol (Appendix 6 - Fig. 1–3, Appendix 7). A total of 537 participants were enrolled in version 2.0 of the protocol from April to July 2017 in Guinea and Liberia. A total of 1,450 participants were enrolled in version 3.0 of the protocol from July 2017 to March 2018 in Guinea and Liberia. Enrollment in version 4.0 occurred over a period of eight months (April to December 2018) with a total of 2,802 participants enrolling in the six sites in the four countries, including 1401 children with an equal distribution between the three age groups. An average of 35.8, 41.4 and 79.2 participants per week were enrolled in version 2.0, 3.0 and 4.0 respectively.

For protocol version 4.0, the proportion of visits attended at M12 was 95.8% whilst for protocol versions 2.0 and 3.0, it was 96.1% and 97.1% respectively.

**Baseline characteristics**

The baseline characteristics of the participants included in all versions of the PREVAC trial are described in Table 1. Overall, the median age was 18 years [IQR: 11–28] and females constituted 45.5% of the study population. Of the 4,789 participants, 2,560 (53%) were adults and 2,229 (47%) were children. Those < 18 years, included 549 (12%) aged 1 to 4 years, 750 (16%) aged 5 to 11 years, and 930 (19%) aged 12–17 years.
Table 1
Baseline characteristics of the participants included in the PREVAC trial

| Country      | Version 2.0 | Version 3.0 | Version 4.0 | All versions |
|--------------|-------------|-------------|-------------|--------------|
|              | No.  | Pct. | No.  | Pct. | No.  | Pct. | No.  | Pct. |
| Guinea       | 263  | 49.0 | 1068 | 73.7 | 999  | 35.7 | 2330 | 48.7 |
| Liberia      | 274  | 51.0 | 382  | 26.3 | 477  | 17.0 | 1133 | 23.7 |
| Sierra Leone | 0    | 0.0  | 0    | 0.0  | 708  | 25.3 | 708  | 14.8 |
| Mali         | 0    | 0.0  | 0    | 0.0  | 618  | 22.1 | 618  | 12.9 |

| Gender       | Version 2.0 | Version 3.0 | Version 4.0 | All versions |
|--------------|-------------|-------------|-------------|--------------|
|              | No.  | Pct. | No.  | Pct. | No.  | Pct. | No.  | Pct. |
| Male         | 333  | 62.0 | 743  | 51.2 | 1536 | 54.8 | 2612 | 54.5 |
| Female       | 204  | 38.0 | 707  | 48.8 | 1266 | 45.2 | 2177 | 45.5 |

| Age          | Version 2.0 | Version 3.0 | Version 4.0 | All versions |
|--------------|-------------|-------------|-------------|--------------|
|              | No.  | Pct. | No.  | Pct. | No.  | Pct. | No.  | Pct. |
| 1–4 years    | 0    | 0.0  | 82   | 5.7  | 467  | 16.7 | 549  | 11.5 |
| 5–11 years   | 0    | 0.0  | 283  | 19.5 | 467  | 16.7 | 750  | 15.7 |
| 12–17 years  | 41   | 7.6  | 422  | 29.1 | 467  | 16.7 | 930  | 19.4 |
| 18–34 years  | 354  | 65.9 | 413  | 28.5 | 946  | 33.8 | 1713 | 35.8 |
| 35–54 years  | 114  | 21.2 | 187  | 12.9 | 368  | 13.1 | 669  | 14.0 |
| ≥ 55 years   | 28   | 5.2  | 63   | 4.3  | 87   | 3.1  | 178  | 3.7  |
| Median (25th, 75th %) | 26 (20–35) | 17 (11–28) | 18 (8–27) | 18 (11–28) |

| Indicators of Increased Risk | Version 2.0 | Version 3.0 | Version 4.0 | All versions |
|------------------------------|-------------|-------------|-------------|--------------|
| Contact with case            | 4           | 0.7         | 7           | 0.5          | 2           | 0.1 | 13 | 0.3 |
| Work entailing contact       | 3           | 0.6         | 1           | 0.1          | 1           | 0.1 | 5  | 0.1 |

| Clinical Examination | Median (25th, 75th %) |
|---------------------|-----------------------|
| Weight (kg)         | 64 (57–71)            |
| Height (cm)         | 167 (160–173)         |
| BMI*                | 22.4 (20.4–25.4)      |

|                      | Version 2.0 | Version 3.0 | Version 4.0 | All versions |
|----------------------|-------------|-------------|-------------|--------------|
| Height (cm)          | 159 (143–168) | 158 (128–168) | 160 (140–169) |               |
| BMI*                 | 20.2 (17.1–23.6) | 20.5 (17.2–23.6) | 20.7 (17.6–23.8) |               |
|                      | Version 2.0 | Version 3.0 | Version 4.0 | All versions |
|----------------------|-------------|-------------|-------------|--------------|
| Arm circumference** (cm) | 15.8 (15.0–16.4) | 15.5 (14.6–16.2) | 15.5 (14.6–16.2) |              |
| Body temperature (°C)  | 36.5 (36.4–36.7) | 36.5 (36.4–36.7) | 36.6 (36.4–36.8) | 36.6 (36.4–36.8) |

### Infection Test Results

|                     | version 2.0 | version 3.0 | version 4.0 | All versions |
|---------------------|-------------|-------------|-------------|--------------|
| HIV positive        | 14          | 2.6         | 15          | 1.0          | 25          | 0.9 | 54          | 1.1          |
| Syphilis positive   | 11          | 2.0         | 16          | 1.1          | 18          | 0.6 | 45          | 0.9          |
| No. Enrolled        | 537         | 1450        | 2802        | 4789         |

* Age 6 years or older

** Age 5 years or younger

At baseline, 13 (0.3%) participants reported having contact with someone with Ebola either recently or in the past, while 5 (0.1%) participants reported that their recent or past work involved contact with a living or dead person with Ebola or with the bodily fluid from a patient.

Among participants enrolled, the median weight at baseline was 54 kg [IQR: 31–65], while the median body mass index (BMI) among participants aged ≥ 6 years was 20.7 [17.6–23.8] at baseline. Among children aged ≤ 5 years, the median mid upper arm circumference was 15 cm [36.4–36.8].

### Baseline laboratory measurements

Biochemical and hematological baseline laboratory measurements are presented pooled for versions 2.0, 3.0 and 4.0 in Tables 2 and 3 for females and males respectively. Laboratory measurements are detailed by country in Appendix – Table 1.
Table 2
Baseline laboratory measurements of female participants included in the PREVAC trial (pooled for versions 2.0, 3.0 and 4.0).

| Baseline Laboratory Measurements: Females | Age 18+ (n = 1118) | Age 12–17 (n = 429) | Age 5–11 (n = 353) | Age 1–4 (n = 276) |
|------------------------------------------|-------------------|-------------------|-------------------|-------------------|
| **Biochemistry**                         |                   |                   |                   |                   |
| ALT (U/L)                                | 10.9 10.6         | 9.3 7.3           | 11.7 11.8         | 13.8 38.2         |
| AST (U/L)                                | 14.2 9.6          | 14.9 6.7          | 20.7 11.6         | 28.9 30.6         |
| Creatinine (mg/dl)                       | 0.80 0.15         | 0.66 0.15         | 0.53 0.13         | 0.38 0.10         |
| Potassium (mmol/L)                       | 4.1 0.4           | 4.2 0.3           | 4.1 0.4           | 4.3 0.5           |
| **Hematology**                           |                   |                   |                   |                   |
| White blood cells (x10³/µL)              | 6.1 2.1           | 6.2 1.8           | 7.0 1.9           | 8.9 2.7           |
| Neutrophils (x10³/µL)                    | 2.9 1.2           | 2.7 1.1           | 2.9 1.4           | 3.2 1.4           |
| Lymphocytes (x10³/µL)                    | 2.5 1.4           | 2.6 0.9           | 3.0 0.9           | 4.5 1.7           |
| Eosinophils (x10³/µL)                    | 0.21 0.26         | 0.26 0.37         | 0.35 0.43         | 0.39 0.64         |
| Monocytes (x10³/µL)                      | 0.46 0.18         | 0.52 0.20         | 0.60 0.22         | 0.77 0.34         |
| Basophils (x10³/µL)                      | 0.08 0.10         | 0.08 0.04         | 0.10 0.05         | 0.15 0.09         |
| Hemoglobin (g/dl)                        | 12.3 1.3          | 12.3 1.3          | 11.9 1.2          | 10.7 1.2          |
| Hematocrit (%)                           | 37.5 3.6          | 37.2 3.5          | 36.0 3.4          | 33.2 3.2          |
| Platelets (x10³/µL)                      | 264.2 71.7        | 288.4 76.4        | 321.4 87.2        | 394.3 111.0       |
| Red blood cells (x10⁶/µL)                | 4.5 0.5           | 4.6 0.5           | 4.6 0.5           | 4.6 0.5           |
| Red cell distribution width (%)          | 13.3 1.6          | 13.3 1.6          | 13.6 1.6          | 14.9 2.3          |
| Mean corpuscular volume (fL)             | 83.8 7.0          | 80.9 7.3          | 78.1 6.4          | 72.8 8.0          |

Note - Lower limit of detection is imputed for undetectable results
Table 3
Baseline laboratory measurements of male participants included in the PREVAC trial (pooled for versions 2.0, 3.0 and 4.0).

| Baseline Laboratory Measurements: Males          | Age 18+ (n = 1440) | Age 12–17 (n = 501) | Age 5–11 (n = 396) | Age 1–4 (n = 273) |
|------------------------------------------------|--------------------|---------------------|--------------------|-------------------|
| **Biochemistry**                                |                    |                     |                    |                   |
| ALT (U/L)                                       | 15.5 28.9          | 13.8 22.3          | 12.8 14.5          | 12.3 16.0         |
| AST (U/L)                                       | 19.8 22.3          | 20.9 17.0          | 21.9 11.6          | 30.2 27.3         |
| Creatinine (mg/dl)                              | 1.00 0.21          | 0.75 0.22          | 0.53 0.14          | 0.39 0.10         |
| Potassium (mmol/L)                              | 4.2 0.4            | 4.3 0.4            | 4.2 0.4            | 4.3 0.5           |
| **Hematology**                                  |                    |                     |                    |                   |
| White blood cells (x10³/µL)                     | 5.4 1.5            | 5.9 1.6            | 7.3 3.4            | 9.0 3.0           |
| Neutrophils (x10³/µL)                           | 2.4 1.1            | 2.4 1.1            | 2.9 1.3            | 3.0 1.3           |
| Lymphocytes (x10³/µL)                           | 2.2 0.7            | 2.5 0.7            | 3.2 2.5            | 4.6 2.1           |
| Eosinophils (x10³/µL)                           | 0.30 0.55          | 0.39 0.50          | 0.54 0.81          | 0.43 0.53         |
| Monocytes (x10³/µL)                             | 0.44 0.16          | 0.53 0.20          | 0.60 0.25          | 0.82 0.33         |
| Basophils (x10³/µL)                             | 0.08 0.03          | 0.09 0.04          | 0.11 0.13          | 0.15 0.08         |
| Hemoglobin (g/dl)                               | 14.2 1.5           | 12.9 1.5           | 11.6 1.2           | 10.4 1.3          |
| Hematocrit (%)                                  | 43.1 4.3           | 39.0 4.2           | 35.0 3.5           | 32.1 3.6          |
| Platelets (x10³/µL)                             | 233.1 67.7         | 270.6 79.3         | 309.2 89.6         | 409.5 139.6       |
| Red blood cells (x10⁶/µL)                       | 5.1 0.6            | 4.9 0.5            | 4.5 0.5            | 4.5 0.6           |
| Red cell distribution width (%)                 | 13.1 1.4           | 13.4 1.6           | 13.7 1.5           | 15.4 2.1          |
| Mean corpuscular volume (fL)                    | 84.8 6.7           | 80.4 6.3           | 77.2 6.0           | 71.5 7.4          |

Note - Lower limit of detection is imputed for undetectable results

Amongst 2,560 adult participants who had an HIV test, 54 (2.1%) tested positive for HIV. All children enrolled in the study were HIV negative at baseline. Both adults and children were tested for syphilis at baseline and 45 (0.9%) participants tested positive and were referred for treatment (Table 1).
Preliminary data on antibody titers at baseline

Preliminary baseline antibody data were available for 23% (1090) of the study population. This sample represented the samples transferred to and processed at the LIBR in Liberia before September 23, 2019. On the 1090 participants, 676 (62%) were from the Mambolo site, 414 (38%) were from Landreah.

At baseline, the median IgG antibody level against EBOV was 72 enzyme-linked immunosorbent assay units (EU) per milliliter (IQR, 50 to 116; 5th and 95th percentiles, 33 to 330). A total of 2.4% of participants had antibody titers of greater than 607 EU/mL; 11.7% had titers greater than or equal to 200 EU/mL (Table 4). These preliminary results indicate that antibody titers prior to vaccination are similar for males (84.2 EU/mL) and females (79.8) and may be higher in adolescent (86.9 EU/mL) and adults (83.7 EU/mL) compared to young children (68.2 EU/mL in 1–4 years old and 78.4 in 5–11 years old) (Appendix 8).

Table 4
Preliminary baseline antibody data (based on a subset of samples of the PREVAC trial participants from version 2.0, 3.0 and 4.0 that were not randomly selected).

| PREVAC Baseline Antibody Titers by Age | No. | GMT* EU/mL | Median (IQR) | 5th, 95th percentile | ≥ 200 EU/mL No. (%) | ≥ 607 EU/mL No. (%) |
|---------------------------------------|-----|------------|--------------|----------------------|---------------------|---------------------|
| All Children                          | 413 | 81.3       | 68 (47, 116) | 30,451               | 54 (13.1%)          | 15 (3.6%)           |
| 1–4 years                             | 44  | 68.2       | 56 (43, 90)  | 26,227               | 4 (9.1%)            | 2 (4.5%)            |
| 5–11 years                            | 162 | 78.4       | 68 (46, 119) | 28,351               | 21 (13.0%)          | 4 (2.5%)            |
| 12–17 years                           | 207 | 86.9       | 71 (49, 117) | 34,470               | 29 (14.0%)          | 9 (4.3%)            |
| All Adults                            | 677 | 83.7       | 74 (52, 114) | 34,317               | 74 (10.9%)          | 11 (1.6%)           |
| 18–25 years                           | 392 | 86.0       | 75 (52, 122) | 33,335               | 45 (11.5%)          | 8 (2.0%)            |
| 26–45 years                           | 205 | 78.7       | 69 (50, 103) | 35,269               | 19 (9.3%)           | 2 (1.0%)            |
| 46 + years                            | 80  | 86.5       | 73 (54, 126) | 37,300               | 10 (12.5%)          | 1 (1.3%)            |
| All Ages                              | 1090| 82.8       | 72 (50, 116) | 33,330               | 128 (11.7%)         | 26 (2.4%)           |

* Geometric mean titer of antibody testing through 22 Sep 2019

Discussion
The successful planning and conduct of this randomized trial of three Ebola vaccine strategies involving six sites within four West African Countries, three sponsors, one NGO, and two pharmaceutical companies is a milestone in collaborative Ebola vaccine research. The results of PREVAC will inform safety and characterize both short-term and long-term immune responses for three vaccine strategies for the prevention of Ebola virus disease in adults and children.

Prior to the design and conduct of PREVAC, most Ebola vaccine phase II trials did not involve children [11]. The involvement of children aged 1–17 in PREVAC is key in evaluating the safety profile of the different candidate vaccines in children. Almost half (2,229 out of 4,789) of participants who enrolled in PREVAC were children aged 1–17 years. Considering that the percentage of children who were infected with EVD during the 2014–2015 epidemic in West Africa, was 16% and these children had a higher case fatality rate than adults [12], the results from this trial will provide important information to guide the vaccination of children in future epidemics such as the one ongoing in DRC where children are being vaccinated.

Whether the different vaccination approaches are able to confer durable antibody responses after vaccination remains an important question and currently limited data exist to address this question. The PREVAC and PREVAC-UP trials will evaluate the durability of immune responses with follow up of the participants up to 60 months after vaccination. These data will provide important information when considering a preventive vaccination strategy for at-risk populations, including health-care and front-line workers who may face ongoing exposure to cases over repeated outbreaks.

The use of a placebo in a clinical trial of a vaccine considered to be efficacious in preventing EVD would be difficult to justify during an active outbreak. However, its use was considered ethical in the current non-epidemic context in the four countries participating in the trial. Placebo controls are an important strength of this trial for the evaluation of safety outcomes. A provision was included in the design of PREVAC that indicated that the use of placebos and the study design would be reconsidered if Ebola returned to these countries during the trial. With the planned long-term follow-up, the same provision will apply. Given the recent licensure of the rVSVΔG-ZEBOV-GP by both the EMA and the FDA, it would be unethical to conduct an efficacy trial with a placebo arm.

The inclusion of the two most promising vaccines was also a strength of the trial. The opportunity to collaborate with the respective companies producing the vaccine and the use of pooled placebo arms were efficient and appropriate given the urgency of the public health need.

There were efforts to achieve equal demographic distribution among participants. An enrollment monitoring team was established to ensure that there was diversity in the ages of children enrolled, especially during enrollment into version 4.0 of the trial. This system allowed a good representation of each age cohort in the trial as was done in PREVAIL I [6].

The design of the trial had to evolve quickly over time to adapt to emerging safety information and the realities of vaccine production. The PREVAC trial began enrollment with version 2.0 with only two arms
and one vaccine strategy while awaiting additional safety investigation on a Merck vaccine lot and the availability of a new lot of the rVSVΔG-ZEBOV-GP vaccine. The 5-arm design was split into two successive phases, version 3.0 (diluted rVSVΔG-ZEBOV-GP) and version 4.0 (undiluted rVSVΔG-ZEBOV-GP), because the lot release potency of rVSVΔG-ZEBOV-GP vaccine was $9.4 \times 10^7$ pfu/mL, which, while within the pre-specified release range of the manufacturer, was greater than the dose with which the investigators had experience in Liberia in PREVAIL I [4]. Variation in the potency in live virus vaccines is common. Vaccine manufacture and release for potency is based upon defined specifications and always encompasses a range with a lower limit. The lower limit is determined during development and is defined by the lowest dose for which there is demonstrated efficacy. The lower limit for potency must still be valid at the end of shelf-life in order to ensure that the vaccine is still efficacious until its defined expiry. Given this, the initial potency of any given lot is typically considerably higher than the nominal dose.

Prior to the conduct of PREVAC, only half the trial sites had prior experience on mobilization and community awareness programs for enrollment and retention of participants in clinical trials. Community engagement is pivotal to recruitment and retention of participants in clinical trials [13,14]. While establishing clinical trial capacity in new sites and upgrading existing sites, community awareness was an integral component that led to achievement of a high rate of enrollment of adults and children in a short period of time and a very low drop-out rate. At most sites, the number of eligible volunteers willing to enroll exceeded the number of participants required. Based on our experience, the development of plans for engaging the community will be an important consideration in future studies carried out by our partnership.

The implementation of a clinical trial such as PREVAC builds and strengthens capacity in clinical research for the personnel involved and physical infrastructure at each site. These personnel have also been able to bring their expertise to other African countries, for example some of site staff went to DRC to strengthen the Ebola clinical research capacity deployed to fight the current epidemic. Such trials can also lead to better training programs for clinical researchers in African institutions.

In conclusion, the results of the PREVAC trial will extend our knowledge of the safety and long-term immunogenicity of the two most promising vaccines to prevent Ebola.

Declarations

Trial Status

The recruitment of participants for this trial has been finished and the one-year follow-up (primary outcome) of the trial was completed by December 24, 2019. The five-year follow-up is planned to be completed in December 2023. The current version of the protocol is version 5.0 (October 3, 2019). This manuscript describing the study protocol was submitted after all participants were included in the different versions of the protocol. This was done in order to be able to present all the versions and to present the baseline characteristics of the participants included in the PREVAC study.
Ethics approval and consent to participate

The study protocol, the informed consent and assent forms, including participants’ information materials, were approved by ethics committees of the sponsors (INSERM IRB 00003888, LSHTM) and the implementing countries (Guinea, Liberia, Mali, and Sierra Leone) before each version of the protocol was implemented. NIH established an institutional reliance agreement with INSERM to rely upon the INSERM ethics committee.

Written informed consent applies to all participants. The informed consent form is available from the corresponding author on request.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Competing interests

None declared.

Authors’ contributions

MB and SBK: investigators at Redemption Hospital; BG, GC, LR, JDN, EL: methodologists; MK: principal investigator for Liberia; AHB: principal investigator for Guinea; SD and SOS: principal investigators for Mali; BL: principal investigator for Sierra Leone; AD: head of the pharmacovigilance working group; DF and RV: head of the lab working group; MK: head of the pharmacy working group; MT: head of the data working group; DW: statistician; HE, HCL, JP, DWJ: sponsor representatives; CR: Trial management team facilitator; ED’O: trial coordinator; YY: Coordinating investigator; All the authors contributed to the writing of the protocol and the manuscript, read and approved the final manuscript.

The use of professional writers is not planned.

Funding

This research was supported in part by the National Institutes of Health (NIH) and by Institut national de la santé et de la recherche médicale (Inserm) and by the London School of Hygiene and Tropical Medicine (LSHTM).

Funding was provided in part by NIAID under NCI contract HHSN261201500003I through the Frederick National Laboratory for Cancer Research. The content of this publication does not necessarily reflect the
views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115854. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA. The dissemination represents only the authors' views and IMI2JU is not responsible for any use of the information contained in the dissemination.

This project has received funding by a dedicated Inserm allocation on behalf the French Research Ministry.

The clinical trial was conducted with the support of Janssen, Bavarian Nordic and Merck Sharp & Dohme Corp. who provided the vaccines.

The funding source has no role in the design of the study, nor collection, analysis, or interpretation of data or writing of the manuscript.

**Acknowledgements**

We are grateful to the Ministries of Health of Guinea, Liberia, Sierra Leone and Mali who permitted the conduct of the trial. We furthermore thank Alima and all site collaborators for their contribution in the implementation of the trial. The authors and study team wish to thank the many participants who contributed to the trial.

**References**

1. Levy, Y., et al. (2018). Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet 392(10149): 787-790.

2. Henao-Restrepo, A. M., et al. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389(10068): 505-518.

3. Milligan, I. D., et al (2016). Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA 315(15):1610-23.

4. Mutua, G., et al (2019). Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. J Infect Dis 220(1):57-67.

5. Anywaine, Z., et al (2019). Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. J Infect Dis 220(1):46-56.
6. Kennedy, S. B., et al. (2017). Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med 377(15): 1438-1447.

7. Logue, J., et al. (2018). Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immunoassay requires fewer study participants to power a study than the Alpha Diagnostic International assay. J Virol Methods 255:84-90.

8. Dosoo DK., et al. (2012). Haematological and biochemical reference values for healthy adults in the middle belt of Ghana. PLoS One 7(4):e36308.

9. Dosoo DK., et al. (2014). Biochemical and hematologic parameters for children in the middle belt of Ghana. Am J Trop Med Hyg 90(4):767-73.

10. Khone B. et al. (2017). Establishing Reference Ranges of Hematological Parameters from Malian Healthy Adults. J Blood Lymph 7(1).

11. Agnandji, S. T., et al. (2017). "Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: A phase I randomised trial." PLoS Med 14(10): e1002402.

12. Garske, T., et al. (2017). Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013-2016. Philos Trans R Soc Lond B Biol Sci 372(1721).

13. Enria L, Lees S, Smout E, Mooney T, Tengbeh AF, Leigh B, et al. Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone. BMC Public Health. 2016;16(1):1140. 10.

14. Laverack G, Manoncourt E. Key experiences of community engagement and social mobilization in the Ebola response. Glob Health Promot. 2016;23(1):79–82